Literature DB >> 17900204

Limitations of contemporary antidepressants: tolerability.

George I Papakostas1.   

Abstract

Antidepressant side effects are common and persistent. They can contribute to discomfort, distress, disability, morbidity, and mortality and can compromise the efficacy of treatments. Reducing the side effect burden, either by developing treatments that have a lower incidence of side effects or by using treatment strategies that alleviate side effects, would improve the standard of care for mood and anxiety disorders. In this article, the rates of common adverse events among the newer (posttricyclic era) antidepressants are compared with those among the selective serotonin reuptake inhibitors, the most popular, contemporary first-line treatments for depression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17900204

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

1.  Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine.

Authors:  Sriparna Ghosal; Eunyoung Bang; Wenzhu Yue; Brendan D Hare; Ashley E Lepack; Matthew J Girgenti; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2017-06-23       Impact factor: 13.382

2.  Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors.

Authors:  Andrea Navarria; Eric S Wohleb; Bhavya Voleti; Kristie T Ota; Sophie Dutheil; Ashley E Lepack; Jason M Dwyer; Manabu Fuchikami; Astrid Becker; Filippo Drago; Ronald S Duman
Journal:  Neurobiol Dis       Date:  2015-06-21       Impact factor: 5.996

3.  Azepines and piperidines with dual norepinephrine dopamine uptake inhibition and antidepressant activity.

Authors:  Dean G Brown; Peter R Bernstein; Ye Wu; Rebecca A Urbanek; Christopher W Becker; Scott R Throner; Bruce T Dembofsky; Gary B Steelman; Lois A Lazor; Clay W Scott; Michael W Wood; Steven S Wesolowski; David A Nugiel; Stephanie Koch; Jian Yu; Donald E Pivonka; Shuang Li; Carol Thompson; Anna Zacco; Charles S Elmore; Patricia Schroeder; JianWei Liu; Christopher A Hurley; Stuart Ward; Hazel J Hunt; Karen Williams; Joseph McLaughlin; Valerie Hoesch; Simon Sydserff; Donna Maier; David Aharony
Journal:  ACS Med Chem Lett       Date:  2012-11-12       Impact factor: 4.345

Review 4.  Insomnia and depression: a multifaceted interplay.

Authors:  Rachel Manber; Andrea S Chambers
Journal:  Curr Psychiatry Rep       Date:  2009-12       Impact factor: 5.285

5.  Long-term body weight outcomes of antidepressant-environment interactions.

Authors:  C Mastronardi; G J Paz-Filho; E Valdez; J Maestre-Mesa; J Licinio; M-L Wong
Journal:  Mol Psychiatry       Date:  2010-12-07       Impact factor: 15.992

Review 6.  How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding.

Authors:  Michael P Hengartner
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-08

7.  M2-AChR Mediates Rapid Antidepressant Effects of Scopolamine Through Activating the mTORC1-BDNF Signaling Pathway in the Medial Prefrontal Cortex.

Authors:  Shuang Liu; Dandan Shi; Zuoli Sun; Yi He; Jian Yang; Gang Wang
Journal:  Front Psychiatry       Date:  2021-05-17       Impact factor: 4.157

Review 8.  Toward achieving optimal response: understanding and managing antidepressant side effects.

Authors:  Karen Kelly; Michael Posternak; Jonathan E Alpert
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

Review 9.  New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder.

Authors:  Cornelius L Katona; Cara P Katona
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-19       Impact factor: 2.570

Review 10.  The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.

Authors:  Antonio Bruno; Paolo Morabito; Edoardo Spina; Maria Rosaria Muscatello
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.